NYXH
Nyxoah S.A. [NYXH] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NYXH Stock Summary
In the News
NYXH Financial details
Company Rating
-
Market Cap
258.24M
Income
-43.21M
Revenue
4.35M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
146
Optionable
No
Shortable
Yes
Earnings
14 May 2024
P/E
-2.58
Forward P/E
-
PEG
-0.89
P/S
30.76
P/B
1.09
P/C
-
P/FCF
-2.08
Quick Ratio
5.32
Current Ratio
5.55
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.56
EPS next Y
-
EPS next Q
-
EPS this Y
28.1%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
86.89%
EPS Q/Q
40.74%
-
-
-
-
SMA20
-
SMA50
-40%
SMA100
-40%
Inst Own
-
Inst Trans
-
ROA
-34%
ROE
-39%
ROC
-0.36%
Gross Margin
64%
Oper. Margin
-1131%
Profit Margin
-1191%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.0-20.0
52W High
-85.35%
52W Low
-26.75%
RSI
42
Rel Volume
0.21
Avg Volume
58.81K
Volume
12.17K
Perf Week
-4.25%
Perf Month
-4.87%
Perf Quarter
-40.45%
Perf Half Y
-47.77%
-
-
-
-
Beta
0.477
-
-
Volatility
0.03%, 0.19%
Prev Close
-2.66%
Price
2.93
Change
-2.01%
Company Profile
- Volume Average 58.81K
- Market Capitalization 258.24M
- Employee 146
- CEO Mr. Olivier Taelman
- Headquarters Mont-Saint-Guibert,BE
- IPO Date 2021-04-28
-
Website
https://www.nyxoah.com 
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
